Dec 17, 2024, 20:31
Outcomes and Trends in Axillary Management of Stage cN3b Breast Cancer Patients
Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared on X:
“Outcomes and Trends in Axillary Management of Stage cN3b Breast Cancer Patients
– Study of 4,236 women with cN3b disease (2012–2021) from NCDB.
– SLNB rates increased from 8.5% (2012) to 35.1% (2021).
– nodal PCR was achieved in 24.9% of patients.
– No significant survival difference between SLNB and ALND in nPCR patients.
Axillary de-escalation strategies may be considered in well-selected cN3b patients with nPCR?”
Outcomes and Trends in Axillary Management of Stage cN3b Breast Cancer Patients
Authors: Julia M. Selfridge, Zachary Schrank, Chris B. Agala, David W. Ollila, Kristalyn K. Gallagher, Dana L. Casey, Philip M. Spanheimer
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 05:54
Dec 21, 2024, 05:42
Dec 21, 2024, 04:55
Dec 21, 2024, 03:42
Dec 21, 2024, 03:31